About this item:

400 Views | 469 Downloads

Author Notes:

Correspondence should be addressed to Robert O. Cotes; robert.o.cotes@emory.edu

Dr. Robert O. Cotes has accepted research funding, consultation fees, and/or honoraria from Alkermes, Janssen, and Otsuka Pharmaceuticals.

Drs. Giordano F. Cittolin-Santos and Jesse C. Fredeen have nothing to disclose.


A Case Report of Mania and Psychosis Five Months after Traumatic Brain Injury Successfully Treated Using Olanzapine.


Journal Title:

Case Reports in Psychiatry


Volume 2017


, Pages 7541307-7541307

Type of Work:

Article | Final Publisher PDF


BACKGROUND: There are few published pharmacologic trials for the treatment of acute mania following traumatic brain injury (TBI). To our knowledge, we present the first case report of an individual being treated and stabilized with olanzapine monotherapy for this condition. CASE PRESENTATION: We describe the case of a 53-year-old African American male admitted to an inpatient psychiatric hospital with one month of behavioral changes including irritability, decreased need for sleep, hyperverbal speech, hypergraphia, and paranoia five months after TBI. Using Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) criteria, he was diagnosed with bipolar disorder due to traumatic brain injury, with manic features. He was serially evaluated with clinical rating scales to measure symptom severity. The Young Mania Rating Scale (YMRS) score upon admission was 31, and the Clinician-Rated Dimensions of Psychosis Symptom Severity (CRDPSS) score was initially 9. After eight days of milieu treatment and gradual titration of olanzapine to 15 mg nightly, his symptoms completely abated, with YMRS and CRDPSS scores at zero on the day of discharge. CONCLUSION: Olanzapine was effective and well tolerated for the treatment of mania following TBI.

Copyright information:

© 2017 Giordano F. Cittolin-Santos et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Export to EndNote